KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Non-Current Liabilities (2017 - 2024)

Bionano Genomics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $41.3 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 61.53% year-over-year to $41.3 million; the TTM value through Dec 2024 reached $41.3 million, down 61.53%, while the annual FY2024 figure was $41.3 million, 61.53% down from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $41.3 million at Bionano Genomics, up from $38.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $107.4 million in Q4 2023 and bottomed at $17.9 million in Q3 2021.
  • The 5-year median for Total Non-Current Liabilities is $41.3 million (2024), against an average of $41.3 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 137.86% in 2023 before it plummeted 61.53% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $25.4 million in 2020, then increased by 21.87% to $30.9 million in 2021, then surged by 45.99% to $45.1 million in 2022, then soared by 137.86% to $107.4 million in 2023, then tumbled by 61.53% to $41.3 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Total Non-Current Liabilities are $41.3 million (Q4 2024), $38.5 million (Q3 2024), and $43.3 million (Q2 2024).